THIS EVENT HAS BEEN CANCELED
The genome-editing technology known as CRISPR has taken the world by storm, with profound implications for genomic research as well as new product development in fields ranging from industrial biotech and agriculture to human diagnostics and therapeutics. A tidal wave of patent filings and a complex network of licensing arrangements make the CRISPR IP landscape difficult to navigate for companies looking to mitigate legal risk in the development of new commercial products. In this talk, Kristin will provide a brief overview of the patent and licensing landscape, the principal legal disputes, and MPEG LA’s initiative to form a neutral and independently managed patent pool to provide a convenient, one-stop license to the foundational Class 2 CRISPR-Cas platform.
Speaker: Kristin Neuman, Executive Director Biotechnology Licensing, MPEG LA, LLC
About our guest speaker:
Kristin Neuman is Executive Director for Biotechnology Licensing at MPEG LA, the world’s leader in the management of patent pools and other collaborative licensing programs. Kristin leads the MPEG LA initiative to form a patent pool for Class 2 CRISPR-Cas. In addition, she heads up business development and licensing for Increscent™ Therapeutics – a biotechnology platform developed by MPEG LA for multimeric oligonucleotide-based therapeutic agents.
Prior to joining MPEG LA, Kristin was an IP lawyer in private practice in New York City. She focused on IP litigation, patent prosecution, and commercial transactions throughout life sciences, consumer products, and medical devices. Kristin received a B.A. in Biochemistry from The University of Colorado, Phi Beta Kappa. She received a J.D. from Georgetown University Law Center and clerked for the late Honorable Roger B. Andewelt of the U.S. Court of Federal Claims.